SMEH Subsidiary Wins Ethamolin Exclusive Saudi Agency

Riyadh, Saudi Arabia — Scientific & Medical Equipment House Company (SMEH) announced that its wholly owned subsidiary, Qarqas Trading Company Pharmaceutical Warehouse, has secured the exclusive distribution agency for Ethamolin® in Saudi Arabia. The agreement runs until 2030 and covers a U.S. Food and Drug Administration-approved drug used to treat bleeding esophageal varices. The counterparty is QOL Medical LLC, a U.S. firm focused on rare disease medicines. The Ministry of Commerce has officially registered the agency.

Ethamolin® is a sclerotherapy drug deployed in gastrointestinal endoscopy units and major referral hospitals. The subsidiary already supplies the drug to the National Unified Procurement Company (NUPCO), the government’s central healthcare procurement body. Those revenues are currently reflected in SMEH’s consolidated financial statements.

Deal Details

The exclusive agency gives Qarqas the sole right to distribute Ethamolin® across the Kingdom through 2030. SMEH is completing the process of registering both the agency and the drug with the Saudi Food and Drug Authority (SFDA). Once the SFDA grants the final license in Qarqas’s name, the subsidiary will hold full regulatory standing to market the product independently. That registration is also expected to broaden the drug’s availability beyond the current government procurement channel.

SMEH CEO Dr. Faisal Al-Atawi framed the deal as both a commercial and strategic move. He described the agency as a responsibility to ensure the availability of a critical medicine in Saudi hospitals, and as a building block in the group’s broader push into specialty pharmaceuticals.

Why It Matters

• Ethamolin® already generates revenue through NUPCO contracts, giving this agency an established commercial base rather than a speculative one.
• SFDA registration, once complete, opens access to private hospitals and clinics beyond the government sector.
• The 2030 term provides revenue visibility across a multi-year horizon.
• The deal advances SMEH’s strategy of building a specialty medicines arm alongside its core medical equipment business.

What This Means for Investors

• Near-term revenue impact is limited — existing NUPCO supply already flows through the subsidiary, so the agency formalizes and extends an existing stream rather than creating an entirely new one.
• The real upside hinges on SFDA approval. Broader market access depends on that license, and the timeline remains subject to regulatory process.
• Investors should watch whether SFDA registration converts into measurable revenue growth beyond the government channel in coming reporting periods.
• The move fits a pattern of SMEH using subsidiaries to build a pharmaceutical distribution portfolio, which could change the company’s revenue mix and valuation profile over time.

Saudi Arabia investor news and market announcements

Saudi capital markets coverage and listed company updates

THE SAUDI STANDARD’S VIEW: SMEH’S ETHAMOLIN PLAY — STRUCTURE OVER SPECULATION

SMEH’s exclusive agency award for Ethamolin® is a measured, strategically coherent move rather than a headline-grabbing acquisition. The deal deserves investor attention precisely because its foundations are already operational — making this a story about consolidation and extension of an existing position, not a bet on an untested product or market.

• AN ESTABLISHED REVENUE BASE PROVIDES RARE DEAL CREDIBILITY

Unlike many agency agreements that require years of market development before generating meaningful returns, Ethamolin® already flows through government procurement channels, giving this arrangement a proven commercial track record. Investors can assess this deal against actual revenue history rather than projected performance. That distinction materially reduces execution risk and raises the quality of the earnings stream being formalized.

• SFDA REGISTRATION IS THE CRITICAL INFLECTION POINT

The transition of full regulatory standing to Qarqas Trading Company opens the door to private hospitals and specialist clinics that currently fall outside NUPCO’s procurement umbrella. Saudi Arabia’s private healthcare sector has expanded significantly in recent years, representing a structurally larger addressable market than government supply contracts alone. Investors should treat SFDA license completion as the primary catalyst to monitor in upcoming quarters.

• THE 2030 TERM ALIGNS WITH SMEH’S PORTFOLIO CONSTRUCTION LOGIC

A multi-year exclusive running to 2030 provides the revenue visibility necessary to justify investment in market development, regulatory compliance infrastructure, and commercial relationships with hospital procurement departments. This timeline also gives Qarqas sufficient runway to entrench its position before any renegotiation. For a company deliberately building a specialty pharmaceutical distribution arm, long-dated exclusivities are the foundational asset class.

• SUBSIDIARY-LED GROWTH SIGNALS A DELIBERATE DIVERSIFICATION STRATEGY

SMEH’s use of Qarqas as the registered agency vehicle, rather than the parent entity directly, reflects a structured approach to pharmaceutical portfolio construction that separates regulatory and commercial risk by business unit. If this model is replicated across additional specialty drugs, the group’s consolidated revenue mix could shift meaningfully toward higher-margin pharmaceutical distribution over time. That evolution would warrant a reassessment of SMEH’s valuation framework by equity analysts.

This transaction sits squarely within Saudi Arabia’s Vision 2030 objective of localizing healthcare supply chains and reducing dependence on fragmented, import-driven distribution networks. As the Kingdom invests in hospital infrastructure and expands healthcare access across its population, domestically anchored distributors holding exclusive agencies for clinically essential drugs occupy an increasingly strategic position. SMEH’s deliberate expansion into specialty pharmaceuticals positions the group to benefit from secular growth in Saudi healthcare spending — provided regulatory execution remains on track.